Sermorelin is marketed for lean muscle, and one human trial does support part of that claim. It is narrower than the marketing, it was run in people aged 55 to 71, and it found the effect in half the participants. Everything else that gets said about sermorelin and muscle — a dose for bodybuilding, a cycle length, a strength gain — is not in the published literature at all.
The one result that exists
In the 1997 trial, nineteen adults took sermorelin nightly for five months against placebo. Lean body mass increased in the men. It did not change in the women [1]. That is nine men and ten women, in one study, never repeated — and the sex split is not a footnote to the result, it is the result. The same trial's outcomes are broken down in full in what the trial actually measured, and the sex-by-sex version is in what it found in women.
Searching PubMed for sermorelin and lean body mass returns two records in total. One is that trial. The other, from 2017, treated hypogonadal men with a growth hormone secretagogue and reported that serum IGF-1 rose [2]. Read the outcome in that title carefully: it is a blood marker, not muscle. A rising IGF-1 confirms the drug is doing something biologically, which is a different claim from a body changing, and the gap between those two things is the single most reliable way sermorelin marketing overstates itself.
What the bodybuilding literature turns out to be
Search sermorelin alongside athletes, bodybuilding or resistance training and PubMed returns four records. Not one of them measures muscle growth. Two are laboratory methods for detecting peptides in doping samples — one a capillary electrophoresis technique for separating GHRH analogs, the other a test method for peptides above 2 kDa. One is a case report about swallowing difficulty in a long-term growth hormone user. The fourth is a 2026 critical review of peptide doping in sport and bodybuilding [3].
So the scientific literature connecting sermorelin to bodybuilding is largely about how to catch it in a urine sample, not about whether it works. That matters practically as well as rhetorically: sermorelin is prohibited at all times by the World Anti-Doping Agency, in and out of competition, and how that differs from a standard workplace drug test is worth understanding before anyone competing goes near it.
There is no bodybuilding dose, because there is no dose-finding study
The trial dose was 10 micrograms per kilogram of body weight, injected nightly [1]. For an 80 kg adult that is about 800 micrograms — and the figure is descriptive, not a protocol. It is what one study gave to older adults, not an amount anybody has shown to be optimal for anything, and no dose-finding study in younger or trained people has been published. PubMed returns a single record for sermorelin and healthy adults.
That is worth holding against what sellers advertise, because the published dose runs above the marketed range rather than below it. Most pages advertise 200 to 300 micrograms nightly, flat, for everyone, and the comparison between the trial dose and the marketed one shows how wide that gap gets at higher body weights. Working out what the trial dose would have been at your own weight is what the dose-by-weight tool does.
What a reader can honestly take from this
If the goal is lean mass, there is one supporting result: men aged 55 to 71, five months, one trial, never replicated. If the goal is strength, there is no measurement at all — the trial did not test it. If the goal is performance in a tested sport, the relevant literature is the detection methods, and the answer is that it is banned.
None of that makes sermorelin useless. It makes the muscle claim far more specific than the marketing, and specific in a way that excludes most of the people searching for it.